Sara Bringhen
Overview
Explore the profile of Sara Bringhen including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
142
Citations
4592
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Fanelli E, Picca G, Airale L, Astarita A, Mingrone G, Catarinella C, et al.
Hypertens Res
. 2025 Jan;
PMID: 39843857
Blood pressure (BP) variability (BPV) is an independent predictor of cardiovascular (CV) events. The role of BPV in defining risk of cancer therapy-related cardiovascular toxicity (CTR-CVT) is currently unknown. The...
2.
Dimopoulos M, Voorhees P, Schjesvold F, Cohen Y, Hungria V, Sandhu I, et al.
N Engl J Med
. 2024 Dec;
PMID: 39652675
Background: Daratumumab, an anti-CD38 monoclonal antibody, has been approved for the treatment of multiple myeloma. Data are needed regarding the use of daratumumab for high-risk smoldering multiple myeloma, a precursor...
3.
Colomba A, Astarita A, Mingrone G, Airale L, Catarinella C, Vallelonga F, et al.
Cancers (Basel)
. 2024 Dec;
16(23).
PMID: 39641752
There was an error in the original publication [...].
4.
Petrucci M, Bringhen S, Entrala Cerezo C, Mendes J, Armeni P
Hematology
. 2024 Nov;
29(1):2432815.
PMID: 39611731
Objective: Patients with multiple myeloma (MM) typically require multiple regimens and become harder to treat with each line of treatment. Furthermore, there is a lack of direct comparative clinical trial...
5.
Bertuglia G, Bringhen S, Bruno B, Impala G, DAgostino M
Br J Haematol
. 2024 Nov;
206(1):16-17.
PMID: 39543460
No abstract available.
6.
Ocio E, Perrot A, Moreau P, Mateos M, Bringhen S, Martinez-Lopez J, et al.
Hemasphere
. 2024 Nov;
8(11):e70041.
PMID: 39507853
No abstract available.
7.
Knop S, Szarejko M, Grzasko N, Bringhen S, Trautmann-Grill K, Jurczyszyn A, et al.
EJHaem
. 2024 Oct;
5(5):940-950.
PMID: 39415900
MP0250 is a designed ankyrin repeat protein that specifically inhibits both vascular endothelial growth factor A (VEGF-A) and hepatocyte growth factor (HGF), aiming at potentiating cancer therapy by disrupting the...
8.
Bertuglia G, Garibaldi B, Casson A, Sarina B, Gay F, Mercadante S, et al.
Bone Marrow Transplant
. 2024 Oct;
60(1):79-82.
PMID: 39367227
No abstract available.
9.
Colomba A, Astarita A, Mingrone G, Airale L, Catarinella C, Vallelonga F, et al.
Cancers (Basel)
. 2024 Sep;
16(17).
PMID: 39272939
Multiple myeloma (MM) affects a population with a high prevalence of cardiovascular (CV) disease. These patients benefit from an accurate CV risk evaluation in order to choose the safest drug...
10.
Fazio F, Petrucci M, Corvatta L, Piciocchi A, Pepa R, Tacchetti P, et al.
EJHaem
. 2024 Jun;
5(3):485-493.
PMID: 38895069
Belantamab mafodotin is the first-in-class antibody-drug conjugates targeting B-cell maturation antigen to have demonstrated effectiveness in triple-class refractory multiple myeloma (TCR-MM) patients. We performed a retrospective study including 78 TCR...